We serve Chemical Name:4-(4-carbamoylphenyl)benzamide CAS:46902-08-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(4-carbamoylphenyl)benzamide
CAS.NO:46902-08-3
Synonyms:4,4′-Biphenyldicarboxamide;Biphenyl-4,4′-dicarbamid;[1,1′-biphenyl]-4,4′-dicarboxamide
Molecular Formula:C14H12N2O2
Molecular Weight:240.25700
HS Code:2924299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:497.3ºC at 760 mmHg
Density:1.25g/cm3
Index of Refraction:1.634
PSA:86.18000
Exact Mass:240.09000
LogP:2.95200
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4,4′-Biphenyldicarboxamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[1,1′-biphenyl]-4,4′-dicarboxamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,4′-Biphenyldicarboxamide Use and application,4,4′-Biphenyldicarboxamide technical grade,usp/ep/jp grade.
Related News: It wasn’t known if this was due to racial differences in breast cancer-related genetic mutations, making it unclear whether race should help guide genetic testing. 4-(4-carbamoylphenyl)benzamide manufacturer At the same time, due to the relatively late development of the bulk drug business in China, most of the established bulk drug companies are currently in the field of commonly used generic drug bulk drugs. Stand up. 4-(4-carbamoylphenyl)benzamide supplier The StartScore model was developed by the company��s in-house supply chain experts based on actual performance data. 4-(4-carbamoylphenyl)benzamide vendor It wasn’t known if this was due to racial differences in breast cancer-related genetic mutations, making it unclear whether race should help guide genetic testing. 4-(4-carbamoylphenyl)benzamide factory Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.
